Hualan Biological Vaccine Inc. (SHE:301207)

Market Cap	9.35B
Revenue (ttm)	1.13B
Net Income (ttm)	205.52M
Shares Out	595.00M
EPS (ttm)	0.34
PE Ratio	45.75
Forward PE	14.69
Dividend	0.20 (1.28%)
Ex-Dividend Date	Jun 14, 2024

Volume	1,059,804
Average Volume	2,873,199
Open	15.93
Previous Close	15.68
Day's Range	15.61 - 15.93
52-Week Range	14.45 - 24.60
Beta	0.79
RSI	39.99
Earnings Date	Mar 29, 2025

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research, development, production, and sale of vaccines in China. It offers influenza virus split vaccines, quadrivalent influenza virus split vaccines, influenza A (H1N1) virus split vaccines, ACYW135 group meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines, group A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccine, and tetanus vaccines, as well as genetic engineering of biological products. The company also sells self-produced products. The company...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 748
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2024, Hualan Biological Vaccine's revenue was 1.13 billion, a decrease of -53.21% compared to the previous year's 2.41 billion. Earnings were 205.52 million, a decrease of -76.10%.